6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.

Abstract:

:A pharmacophore model for triple reuptake inhibitors and the new class of 1-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes were recently reported. Further investigation in this area led to the identification of a new series of potent and selective triple reuptake inhibitors endowed with good developability characteristics. Excellent bioavailability and brain penetration are associated with this series of 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptanes together with high in vitro potency and selectivity at SERT, NET, and DAT. In vivo microdialysis experiments in different animal models and receptor occupancy studies in rat confirmed that derivative 17 showed an appropriate profile to guarantee further progression of the compound.

journal_name

J Med Chem

authors

Micheli F,Cavanni P,Andreotti D,Arban R,Benedetti R,Bertani B,Bettati M,Bettelini L,Bonanomi G,Braggio S,Carletti R,Checchia A,Corsi M,Fazzolari E,Fontana S,Marchioro C,Merlo-Pich E,Negri M,Oliosi B,Ratti E,Read K

doi

10.1021/jm100481d

subject

Has Abstract

pub_date

2010-07-08 00:00:00

pages

4989-5001

issue

13

eissn

0022-2623

issn

1520-4804

journal_volume

53

pub_type

杂志文章